Why DexCom Stock Is Trading Lower Friday
Why DexCom Stock Is Trading Lower Friday
As for guidance, DexCom sees third quarter revenue between $975 million and $1 billion versus analyst estimates of $1.15 billion. Dexcom sees revenue for the 2024 fiscal year between $4 billion and $4.05 billion versus analyst estimates of $4.33 billion. DexCom, Inc. (NASDAQ:DXCM) shares are moving lower Friday after the company reported worse-than-expected second quarter revenue and issued weak guidance.
德康醫療股份有限公司（NASDAQ:DXCM）股價週五下跌，因公司報告第二季度營收低於預期併發出疲弱業績預報。
What Happened: DexCom reported 2024 fiscal year second quarter earnings after the market closed on Thursday. The company reported adjusted EPS of 43 cents beating analyst estimates of 39 cents.
發生了什麼：DexCom在週四收盤後報告了2024財年第二季度業績。公司報告每股調整後的收益爲43美分，超過分析師預估的39美分。
DexCom also reported quarterly revenue of $1.04 billion missing analyst estimates of $1.36 billion. This figure represents a 15% year-over-year growth.
DexCom還報告稱季度營收爲10.4億美元，低於分析師預估的13.6億美元。這一數字代表了15%的年增長。
As for guidance, DexCom sees third quarter revenue between $975 million and $1 billion versus analyst estimates of $1.15 billion. Dexcom sees revenue for the 2024 fiscal year between $4 billion and $4.05 billion versus analyst estimates of $4.33 billion.
至於業績預報，DexCom預計第三季度營收爲0.975億美元至10億美元，而分析師預估爲11.5億美元。Dexcom預計2024財年營收爲40億美元至40.5億美元，而分析師預估爲43.3億美元。
Dexcom included several highlights from the second quarter in its earnings report, including securing coverage for Dexcom ONE in France for certain people with type 2 diabetes and it launched Direct-to-Watch in the U.S. and several other markets worldwide.
Dexcom在其業績中列出了第二季度的一些亮點，包括在法國爲某些2型糖尿病患者獲得Dexcom ONE的覆蓋，並在美國和全球其他幾個市場推出了Direct-to-Watch。
"While Dexcom advanced several key strategic initiatives in the second quarter, our execution did not meet our high standards," said Kevin Sayer, Dexcom's chairman, president and CEO.
“雖然Dexcom在第二季度推進了幾個關鍵戰略計劃，但我們的執行沒有達到我們的高標準，”德康醫療主席、總裁兼首席執行官Kevin Sayer說道。
"We have a unique opportunity to serve millions of more customers around the world with our differentiated product portfolio and we are taking action to improve our execution and best position ourselves for continued long-term growth."
“我們有一個獨特的機會，用我們的差異化產品組合爲全球數百萬客戶服務，我們正在採取行動改善我們的執行並最好地爲持續的長期增長做好準備。”
Analyst Changes: Following the earnings report, multiple analysts issued price target changes.
分析師變化：發佈業績後，多個分析師發佈了價格目標的變化。
- JP Morgan analyst Robbie Marcus downgrades DexCom from Overweight to Neutral and lowers the price target from $145 to $75.
- Canaccord Genuity analyst William Plovanic maintains DexCom with a Buy and lowers the price target from $145 to $89.
- Wells Fargo analyst Larry Biegelsen maintains DexCom with a Overweight and lowers the price target from $145 to $80.
- RBC Capital analyst Shagun Singh maintains DexCom with a Outperform and lowers the price target from $165 to $145.
- Piper Sandler analyst Matt O'Brien maintains DexCom with a Overweight and lowers the price target from $150 to $90.
- JP摩根分析師Robbie Marcus將德康醫療的評級從超配降至中立，並將價格目標從145美元降至75美元。
- Canaccord Genuity分析師William Plovanic維持德康醫療的買入評級，並將價格目標從145美元降至89美元。
- 威爾斯·法戈分析師Larry Biegelsen維持德康醫療的超配評級，並將價格目標從145美元降至80美元。
- RBC Capital分析師Shagun Singh維持對德康醫療的跑贏大市評級，並將價格目標從165美元降至145美元。
- 派傑投資分析師Matt O'Brien維持德康醫療的超配評級，並將價格目標從150美元降至90美元。
DXCM Price Action: At the time of writing, DexCom stock is trading 40.2% lower at $64.45 per data from Benzinga Pro.
DXCM股票目前正以64.45美元的價格交易，跌幅爲40.2%，數據來源於Benzinga Pro。
Image: Courtesy of DexCom
圖片：DexCom提供的圖像。
